statistiche ricercatore

Nazione	#
IT - Italia	12.249
US - Stati Uniti d'America	1.067
SG - Singapore	225
CN - Cina	125
BR - Brasile	77
VN - Vietnam	67
SE - Svezia	65
FI - Finlandia	28
DE - Germania	23
FR - Francia	23
HK - Hong Kong	14
IN - India	13
CA - Canada	11
GB - Regno Unito	11
ZA - Sudafrica	9
AR - Argentina	8
BD - Bangladesh	7
KR - Corea	6
MX - Messico	6
UA - Ucraina	6
AT - Austria	5
IQ - Iraq	5
NL - Olanda	5
TR - Turchia	5
UZ - Uzbekistan	5
BE - Belgio	4
JP - Giappone	4
MY - Malesia	4
AE - Emirati Arabi Uniti	3
ES - Italia	3
IE - Irlanda	3
PK - Pakistan	3
PL - Polonia	3
SA - Arabia Saudita	3
BO - Bolivia	2
CL - Cile	2
CO - Colombia	2
CZ - Repubblica Ceca	2
GR - Grecia	2
HU - Ungheria	2
ID - Indonesia	2
KZ - Kazakistan	2
LT - Lituania	2
PE - Perù	2
PH - Filippine	2
RU - Federazione Russa	2
UY - Uruguay	2
AD - Andorra	1
AL - Albania	1
AU - Australia	1
CR - Costa Rica	1
EC - Ecuador	1
ET - Etiopia	1
IL - Israele	1
IR - Iran	1
JO - Giordania	1
KE - Kenya	1
KG - Kirghizistan	1
KH - Cambogia	1
LA - Repubblica Popolare Democratica del Laos	1
LB - Libano	1
MD - Moldavia	1
NZ - Nuova Zelanda	1
OM - Oman	1
PS - Palestinian Territory	1
PY - Paraguay	1
RO - Romania	1
ZW - Zimbabwe	1
Totale	14.142

Nome	#
Performance in daily activities, cognitive impairment and perception in multiple sclerosis patients and their caregivers	3.660
Cognition in multiple sclerosis: Between cognitive reserve and brain volume	2.870
Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study	2.093
Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study	1.029
Leukocyte telomere length in women with multiple sclerosis: Comparison with healthy women during pregnancy and puerperium	728
An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis	581
What happens after fingolimod discontinuation? A multicentre real-life experience	564
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies	544
Brain Volume and Perception of Cognitive Impairment in People With Multiple Sclerosis and Their Caregivers	486
Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study	470
Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis Patients	470
The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility	439
Implications of disease-modifying therapies for multiple sclerosis on immune cells and response to COVID-19 vaccination	256
Totale	14.190

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	482	0	0	0	0	0	0	0	0	0	182	183	117
2021/2022	891	59	29	47	62	38	26	34	53	114	117	168	144
2022/2023	1.628	100	243	247	129	123	223	92	109	88	85	108	81
2023/2024	1.677	167	86	60	96	143	272	221	146	80	125	145	136
2024/2025	3.494	697	891	352	347	197	191	287	19	49	53	339	72
2025/2026	1.161	103	59	117	120	105	97	289	100	66	105	0	0
Totale													14.190

UNICA IRIS Institutional Research Information System